Cardiovascular Toxicity and Clinical Outcomes Following Chimeric Antigen Receptor T-Cell Infusion (CART) for Lymphoid Malignancies

CART-cell therapy is associated with dramatic efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma and B-acute lymphoblastic leukemia. However, the efficacy of CART therapy is limited by potentially fatal toxicities including cytokine release syndrome (CRS) and neurotoxicity. Increasingly, emerging reports have suggested the potential for significant hemodynamic collapse following CART therapy. Yet, whether the occurrence of these hemodynamic shifts or any other cardiovascular disease (CVD) events have bearing on clinical outcomes after CART initiation is unknown.

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Jonathan E. Brammer, Zachary Braunstein, Aashish Katapadi, Kyle Porter, Michael Biersmith, Avirup Guha, Sakima A. Smith, Sumithira Vasu, Devin Haddad, Richard Gumina, Basem M. William, Sam Penza, Ayman Saad, Nathan Denlinger, Ajay Vallakati, Ragavendra Ba Tags: 407 Source Type: research